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hallmark of peroxynitrite-mediated oxidant injury, which
can be quantified immunohistochemically.5
In an established rabbit model of extremity reperfu-
sion injury, we have demonstrated direct evidence of skele-
tal muscle oxidant injury by the peroxynitrite anion.3 This
model had been refined to permit the microscopic obser-
vation of early tyrosine nitration after 3 hours of ischemia
and 2 hours of reperfusion, where grossly the muscle
exhibits only tissue edema. In this manner, confounding
variables related to profound tissue necrosis were obvi-
ated, permitting the elucidation of early inflammatory par-
ticipants related to neutrophil-derived free radicals.
Platelet endothelial cell adhesion molecule-1 (PECAM-1)
(CD-31), a member of the immunoglobulin-associated cell
adhesion molecule family, is present on neutrophils and
endothelial cells and mediates the final common pathway of
neutrophil transendothelial migration.6 Monoclonal antibod-
ies directed against PECAM-1 inhibit neutrophil trans-
endothelial migration in vitro.7 In several animal models of
myocardial reperfusion injury, the administration of anti–
PECAM-1 monoclonal antibodies produced a significant
reduction in infarct size.8,9
PECAM-1 exerts its effects in vivo through homo-
philic binding between respective PECAM-1 on the emi-
grating neutrophil and the resident endothelial cell.10 This
The understanding of neutrophil-mediated skeletal
muscle oxidation during extremity reperfusion is pivotal in
the development of therapeutic agents to inhibit this
process. Early evidence of neutrophil activation resides in
the venous effluent of the reperfused extremity, where an
ex vivo increase in neutrophil-derived free radical produc-
tion can be seen.1 Reperfused skeletal muscle reveals
increased levels of neutrophil-derived myeloperoxidase,
evidence of neutrophil participation in skeletal muscle oxi-
dant injury.2 Peroxynitrite anion is a toxic product of nitric
oxide and superoxide anion, both neutrophil-derived free
radicals. It is a highly reactive species that contributes to
cellular injury by oxidizing carbohydrates, sulfhydrils,
lipids, and DNA bases, and by nitrating protein residues.3,4
Tyrosine residues are nitrated to produce nitrotyrosine, a
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Objective: Neutrophil transendothelial migration, a key feature of skeletal muscle ischemia and reperfusion (I/R) injury,
is mediated by the platelet endothelial cell adhesion molecule-1 (PECAM-1). Peroxynitrite anion, a toxic product of
neutrophil superoxide anion and nitric oxide, contributes to oxidative skeletal muscle injury and can be quantified by
measurement of protein tyrosine nitration after I/R. This study hypothesizes that administration of the PECAM-
1/IgG antibody chimera will inhibit peroxynitrite-mediated injury after I/R.
Methods: The study was composed of five groups: an I/R group (n = 4), a sham treatment group anesthetic control (n =
3), a treatment group receiving the PECAM-1/immunoglobulin G (IgG) antibody chimera with I/R (n = 9), a treat-
ment group receiving human IgG with I/R as an antibody control (n = 6), and a treatment group receiving normal saline
solution with I/R as a vehicle control (n = 5). The right hind limb in male New Zealand white rabbits was rendered
ischemic by occluding the iliac and femoral arteries for 3 hours, followed by 2 hours of reperfusion (I/R). Sham-treated
rabbits underwent arterial dissection without arterial occlusion. PECAM-1/IgG–treated rabbits and IgG-treated rab-
bits received an infusion of 1 mg/kg in normal saline solution 20 mL via an ear vein catheter during the last 5 minutes
of ischemia and the first 15 minutes of reperfusion. Saline solution–treated rabbits similarly received normal saline solu-
tion 20 mL. The anterior tibialis muscle was harvested after reperfusion. Immunohistochemical staining for nitrotyro-
sine was performed with monoclonal antinitrotyrosine antibodies and fluorescently labeled secondary antibodies.
Computed morphometric study was performed to calculate relative fluorescence scores for each histologic section.
Averaged fluorescence scores were analyzed by one-way analysis of variance with Bonferroni post hoc comparison.
Results: The averaged fluorescence scores (mean ± SEM) for the sham-treated (2.88 ± 0.78) and PECAM-
1/IgG–treated (6.16 ± 0.43) groups demonstrated a significant reduction in quantitative fluorescence compared with
the IgG- (15.17 ± 2.01) and saline solution–treated (17.46 ± 3.71) control groups, and the I/R-treated (18.52 ± 3.00)
group, (P < .05).
Conclusions: These results suggest that PECAM-1/IgG diminishes peroxynitrite-mediated oxidative skeletal muscle
injury by inhibiting neutrophil transendothelial migration and may therefore prove a useful therapeutic agent in the
treatment of reperfusion injury. (J Vasc Surg 2001;34:555-8.)
is unlike other intercellular adhesion molecules, which
have complementary receptor complexes (neutrophil β2
integrins) to mediate intercellular adhesion.
Because of its unique homophilic binding properties,
exogenous isogeneic PECAM-1 can be administered,
instead of a xenogeneic monoclonal antibody, to bind with
endogenous PECAM-1. Advantages to this strategy
include the avoidance of leukocyte depletion through anti-
body-mediated opsonization and the prevention of host-
neutralizing antibody production, which would preclude
repeated therapy.
This study used a novel human PECAM-1 antibody
chimera, the fusion product of two extracellular regions of
human PECAM-1 with the Fc portion of human
immunoglobulin (IgG).11 By binding two PECAM-1
molecules to one IgG Fc region, the affinity of the
chimera to endogenous PECAM-1 was effectively dou-
bled on a molar basis, which increased the potency of this
“immunoadhesin.” Prior use of PECAM-1/IgG has
demonstrated inhibition of neutrophil transendothelial
migration in a peritonitis model.12
This study evaluated the administration of PECAM-
1/IgG with extremity reperfusion. Binding the endoge-
nous PECAM-1 on circulating neutrophils just before
reperfusion or endothelial PECAM-1 during reperfusion
may inhibit subsequent neutrophil transendothelial migra-
tion within the reperfused extremity. We hypothesized
that the intravenous administration of PECAM-1/IgG
during late ischemia and early reperfusion would diminish
subsequent neutrophil-mediated extremity reperfusion
injury, as measured by a reduction in peroxynitrite-medi-
ated skeletal muscle oxidation.
METHODS
PECAM-1/IgG and IgG. The cDNA sequence
encoding the extracellular domains of human PECAM-1
were spliced with those encoding the Fc portion of human
immunoglobulin. The product was transfected into
Chinese hamster ovary cells and mass-produced.11 The
PECAM-1/IgG was stored in phosphate-buffered saline
solution (PBS) at –70°C before use. Human polyclonal
IgG was obtained from Sigma Corporation (St Louis, Mo).
Animal protocol. Twenty-seven male New Zealand
white rabbits (3 kg) were divided into five groups (n):
sham (anesthesia control = 3), PECAM-1/IgG (experi-
mental group = 9), IgG (human immunoglobulin anti-
body control = 6), saline solution (vehicle control = 5),
and I/R (ischemia/reperfusion group = 4). A preanes-
thetic consisting of subcutaneous ketamine (44 mg/kg),
xylazine (5 mg/kg), and acepromazine (0.7 mg/kg) was
administered, followed by continuous intravenous anes-
thesia with alpha-chloralose (20 mg/kg per hour) through
a dorsal ear vein. Mechanical ventilation was maintained
through a tracheostomy. Continuous blood pressure mon-
itoring was performed through a carotid artery cannula.
Body temperature was maintained with a heating pad.
I/R protocol. Each rabbit underwent a standard
exposure of the aortoiliac and right femoral arteries
through a midline laparotomy and right groin dissection,
respectively. Ligation of pelvic arterial collateral vessels was
performed. Sham-treated rabbits were maintained under
anesthesia for 5 hours. The remaining four groups under-
went an established I/R protocol, where clamps were
placed on the right common iliac and right femoral arter-
ies to render the limb completely ischemic, confirmed by
the absence of a Doppler signal on the common femoral
artery below its clamp.13 After 3 hours of ischemia, the
clamps were removed, and flow restoration was confirmed
by serial Doppler examination. After 2 hours of reperfu-
sion, segments of the anterior tibialis muscle were excised
and flash-frozen with liquid nitrogen for immunohisto-
chemical assessment.
Infusion protocol. Three of the four groups that
underwent the I/R protocol received 20 mL of the appro-
priate intravenous agent during the final 5 minutes of
ischemia and the first 15 minutes of reperfusion, for a total
infusion time of 20 minutes. PECAM-1/IgG–treated and
IgG-treated rabbits received a dose concentration of 1
mg/kg in normal saline solution. This dose was calculated
empirically to bind systemic neutrophils before reperfu-
sion. This concentration approached the oncotic pressure
equivalent of serum albumin, prompting a saline solu-
tion–treated control group to account for any changes
possibly related to this effect. Saline solution–treated rab-
bits received normal (0.9%) saline solution. I/R-treated
rabbits received no infusion.
Animal care. All rabbits were killed with high-dose
intravenous pentobarbital. The procedures performed on
the rabbits were approved by the animal research commit-
tee and conformed to guidelines outlined in the Guide for
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Skeletal muscle tyrosine nitration by peroxynitrite was assessed
through quantitative image analysis of immunofluorescence
images from each of five groups. These data are displayed as aver-
aged fluorescence scores. Sham-treated and PECAM-1/IgG–
treated groups demonstrated significant reduction in fluorescence
compared with three control groups. This signifies parallel reduc-
tion in degree of peroxynitrite-mediated skeletal muscle tissue
oxidation incurred during reperfusion.
the Care and Use of Laboratory Animals (Department of
Health and Human Services, National Institutes of Health
85-23, revised 1985).
Immunohistochemical protocol. Frozen muscle sam-
ples were sectioned into 8.0-µm thickness slices and placed
on glass slides for further staining. An established immuno-
fluorescence monoclonal antibody staining technique was
used to quantify protein tyrosine nitration.14 Slides were
washed with 0.1 mol/L PBS, pH 7.2, and incubated twice
for 3 minutes with sodium borohydride solution 0.5
mg/mL. The slides were then incubated for 1 hour with a
blocking solution consisting of 4% fatty-acid free bovine
serum albumin, 10% goat serum in 0.1 mol/L PBS, pH 7.2,
and 0.3% Triton X-100. The slides were again blocked for 2
hours with the antinitrotyrosine primary antibody (mouse
clone 1A6) (Upstate Biotechnology, Lake Placid, NY),
diluted in blocking solution within a humidified chamber.
The slides were washed for 5 minutes with 0.1 mol/L PBS,
pH 7.2, and 0.3% Triton X-100 between each step. The
slides were then incubated for 1 hour with anti-mouse goat
secondary antibody labeled with Cy3, (clone 1A4) (Accurate
Chemical, Westbury, NY), and diluted in blocking solution
at 1:250. The slides were washed in solutions of 0.1 mol/L
PBS with decreasing concentrations of Triton X-100 and air-
dried.
Microscopy and fluorescence measurement. After
the proper mounting with an aqueous medium, slides
were analyzed with a fluorescent lamp by use of rho-
damine filters at original magnification ×40. Images were
acquired by use of a real-time video camera with an inte-
gration time of 0.2 seconds. The images were quantita-
tively analyzed with Metamorph 2.5 software (Universal
Imaging Corp, Downingtown, Pa). Acquired images were
assessed by a “blinded” observer for the intensity/bright-
ness of fluorescence. Background brightness from repre-
sentative unstained slides was subtracted from the
antibody-exposed slides to amplify the true luminescent
signal intensity. The value for intensity was unitless, a
scaled numeric value assessed by the morphometry soft-
ware. Of importance is the consistent use of the rho-
damine filter, magnification factor, and video camera
integration time to assure reproducible values. A compos-
ite fluorescence value was determined for each experimen-
tal animal by averaging six randomly scanned sections
from each slide. This mean value represented total fluo-
rescence for each animal and was submitted for statistical
analysis.
Statistical analysis. Statistics were performed with
SPSS software (SPSS Inc, Chicago, Ill). Averaged fluores-
cence scores were analyzed by one-way analysis of variance
with Bonferroni post hoc comparison. Data were pre-
sented as mean ± SEM, accepting a CI of 95% (P < .05).
RESULTS
The averaged fluorescence scores (mean ± SEM) for the
sham-treated (2.88 ± 0.78) and PECAM-1/IgG–treated
(6.16 ± 0.43) groups demonstrated a significant reduction
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in quantitative fluorescence compared with the IgG- (15.17
± 2.01) and saline solution–treated (17.46 ± 3.71) control
groups and the I/R-treated (18.52 ± 3.00) group (Figure)
(P < .05).
DISCUSSION
PECAM-1/IgG inhibits skeletal muscle oxidation.
Peroxynitrite-mediated skeletal muscle oxidation was sig-
nificantly reduced by the intravenous administration of the
PECAM-1/IgG immunoadhesin with reperfusion. This
was supported by the persistence of tyrosine nitration in
the presence of IgG- and saline solution–treated controls.
PECAM-1/IgG may mediate its effect through the inhi-
bition of neutrophil transendothelial migration. Similar
observations have been made by use of monoclonal anti-
bodies toward PECAM-1 in several different animal mod-
els of myocardial reperfusion injury and peritonitis.8,9 In
both the feline and rodent models of myocardial reperfu-
sion injury, anti–PECAM-1 monoclonal antibodies
administered during ischemia reduced postreperfusion
infarct size.
Peroxynitrite formation may be neutrophil derived.
This study used the technique of quantifying tissue free rad-
ical injury by measuring nitrotyrosine levels, which are
dependent on peroxynitrite production. During reperfusion,
neutrophils and endothelial cells can produce superoxide
anion and nitric oxide. We have found that endothelial cells
are dysfunctional after reperfusion, producing diminished
amounts of nitric oxide as exhibited by reduced endothe-
lium dependent vasorelaxation.13 The data from our study
suggest that an alteration in neutrophil-derived free radicals
may therefore be responsible for diminished peroxynitrite
production and may be associated with the effects of
blocked transendothelial migration.
Endothelial PECAM-1 is pathologically altered
during reperfusion. The specific mechanism by which
PECAM-1 permits neutrophil transendothelial migration
during reperfusion has been studied in vitro. Under con-
ditions of oxidative stress, the phosphorylation of
endothelial PECAM-1 is the inciting step in promoting
neutrophil transendothelial migration.15 In this model,
PECAM-1/IgG may prevent interactions between neu-
trophil PECAM-1 and this phosphorylated form of
endothelial PECAM-1.
PECAM-1/IgG administration is clinically feasible.
This experimental model was well suited to simulate the
clinical presentation of acute limb ischemia. The infusion
was timed to occur during the early phase of reperfusion,
when most of the inflammatory activation events were
known to occur. The infusion was initiated 5 minutes
before reperfusion to establish an adequate serum immuno-
adhesin concentration before the onset of reperfusion. The
infusion was continued into the first 15 minutes of reperfu-
sion. In this manner, PECAM-1/IgG could potentially
bind circulating neutrophil PECAM-1 when administered
just before reperfusion. Once reperfusion has begun, part of
the mechanism of action may involve immunoadhesin bind-
ing to endothelial PECAM-1 within the reperfused skeletal
muscle. We favored an intravenous route of infusion both to
potentially pretreat systemic neutrophils and to avoid a
rapid washout of the agent, which might occur with an
intraarterial infusion.
Untoward effects on neutrophil function by PECAM-
1/IgG are presently unknown. The isogeneic nature of
PECAM-1/IgG obviated the risks of xenogeneic mono-
clonal antibodies, which are known to destroy bound neu-
trophils through antibody opsonization, leading to
neutropenia and potential host immunosuppression. This
would permit repeat administration of the agent if the
need were to arise.
CONCLUSION
PECAM-1/IgG administered during ischemia and
reperfusion prevented skeletal muscle injury as reflected
by the diminished oxidative activity of peroxynitrite. The
ability to engineer nonnaturally occurring yet immuno-
compatible therapeutic agents such as the PECAM-1
immunoadhesin may provide a superior means of treating
reperfusion injury.
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